On August 28, 2026, the FDA issued marketing granted orders for the JUUL2 e-cigarette device and two flavored pods — Virginia Tobacco and Polar Menthol — both at 18 mg/mL (1.5–1.6% nicotine). The authorization brings the total number of FDA-authorized e-cigarette products to 48 and marks a pivotal moment: it is only the second time the agency has cleared a menthol-flavored pod under the PMTA pathway, and the first time JUUL's next-generation platform has received a green light in the United States.

The Regulation in Plain English

Here's what the FDA actually did: it granted marketing granted orders (MGOs) for three products within the JUUL2 system — the device itself, a Virginia Tobacco pod, and a Polar Menthol pod. Both pods contain 18 mg/mL of nicotine, equivalent to roughly 1.5–1.6% concentration. This is notably lower than the 5% (59 mg/mL) concentration that made the original JUUL controversial.

An MGO means JUUL Labs can legally market and sell these specific products in the United States. It does not mean the FDA has declared them "safe" or "FDA-approved." It means the agency determined that, on balance, the products are "appropriate for the protection of the public health" — the statutory standard under the Family Smoking Prevention and Tobacco Control Act.

The FDA's reasoning rested on three pillars:

• Adult switching: A substantial proportion of adult smokers completely switched from combustible cigarettes to JUUL2 products within six weeks. The menthol pod outperformed the tobacco pod.
• Reduced exposure: Adults who switched completely were exposed to lower levels of harmful chemicals than if they had continued smoking.
• Benefit-risk balance: For the menthol product specifically, FDA concluded the added benefit to adult smokers was sufficient to outweigh the risks, including youth appeal.

The menthol determination is the headline. Menthol has historically faced a steeper regulatory climb than tobacco flavor in the PMTA process. By explicitly weighing the higher switching rate against youth appeal — and siding with adult benefit — the FDA has set a precedent that other manufacturers will inevitably cite in their own flavor applications.

What the Switching Data Actually Shows

The FDA presented switching rates as ranges rather than point estimates:

The gap between the two flavors is significant: the menthol pod's floor (28.4%) exceeds the tobacco pod's ceiling (34.6%). This is the evidence the FDA used to justify authorizing a menthol-flavored product despite long-standing concerns about menthol's appeal to youth.

Who's Affected?

For Adult Consumers Who Smoke

The JUUL2 system offers another FDA-authorized alternative to combustible cigarettes. The 18 mg/mL nicotine concentration is designed to compete with the satisfaction of traditional cigarettes. JUUL2 also includes technology features not present in the original JUUL: a Pod ID chip that prevents use of counterfeit pods, Bluetooth connectivity, a 21+ age-gated smartphone app, and device-locking capability. Consumers should understand that the FDA's authorization is based on complete switching — dual use (smoking and vaping) does not provide the same degree of health benefit.

For Retailers

Authorized JUUL2 products can be legally sold in states where e-cigarette sales are permitted. However, retailers must navigate an increasingly complex state-level regulatory landscape. As of September 2026, roughly 14+ states have implemented PMTA registry or directory systems that add a second layer of market-access requirements on top of FDA authorization. West Virginia's Vape Safety Act, effective September 1, 2026, prohibits sale of products not listed on the state directory, with civil penalties for non-compliant sellers. Retailers must verify that products appear on both federal and state lists.

For Manufacturers and Competitors

The JUUL2 authorization extends the pool of FDA-authorized e-cigarettes to 48 products. JUUL Labs has signaled it will file additional PMTAs for 5% nicotine concentration products and "a portfolio of flavors — beyond tobacco and menthol." If the FDA's menthol reasoning holds as precedent, other manufacturers with pending flavor applications — particularly those involving flavors like mango or blueberry, which FDA already authorized for Glas products in May 2026 — may see a clearer (if still demanding) path to authorization.

JUUL's Regulatory Journey: A Timeline

What to Do Now: Actionable Checklists

US vs UK Comparison

Notably, JUUL2 was first launched in the UK in 2021, meaning British consumers have had access to the next-generation platform for roughly five years before it reached the US market. The UK's TPD framework — which caps nicotine at 20 mg/mL — means the JUUL2's 18 mg/mL pods are compliant in both jurisdictions. The UK's disposable vape ban, which took effect in June 2025, contrasts with the US's patchwork approach, where only California has passed comparable legislation (AB 762, August 2026).

What's Next? Predictions Based on Precedent

1. JUUL Will Pursue Broader Flavor and Nicotine Applications

CEO K.C. Crosthwaite explicitly stated the company will file PMTAs for "5% nicotine concentration products and a portfolio of flavors — beyond tobacco and menthol." Given that the FDA authorized mango (Glas Gold) and blueberry (Glas Sapphire) flavors in May 2026, JUUL has a clearer signal that non-tobacco/menthol flavors can pass the benefit-risk test. Expect filings within 6–12 months.

2. PMTA Review Times Will Continue to Shorten

The FDA's Center for Tobacco Products reported reducing its PMTA backlog by approximately 70% during 2025. The nicotine-pouch pilot program — which produced on! PLUS authorizations just three months after scientific review began — has been described as a PMTA review record. These efficiency measures are being applied to other PMTAs. The JUUL2 authorization, coming roughly three years after the initial 2023 filing, reflects this acceleration.

3. State Regulation Will Diverge Further

Even as the federal authorized product list grows, states are creating their own market-access layers. Key developments in September 2026:

• New York: 75% wholesale tax on nicotine pouches and alternative nicotine products took effect September 1, 2026, with a floor tax on existing inventory due September 21
• West Virginia: Vape Safety Act directory enforcement began September 1, 2026 — products not on the state list cannot be sold
• California: AB 762 banning single-use disposable vapes passed the legislature and awaits the Governor's signature
• Hawaii: New law requires FDA marketing granted orders (not just pending PMTAs) for state directory eligibility, effective for 2027
• Utah: 71% tax on e-cigarettes and 73% on non-pouch alternative nicotine products, with $1.00-per-can tax on pouches

The result: a product that is FDA-authorized may still be illegal to sell in multiple states. Manufacturers and retailers face a compliance landscape that is federally expanding but state-by-state contracting.

4. The Menthol Precedent Will Be Tested

The FDA's explicit determination that menthol's adult-switching benefit outweighs youth-appeal risk will be cited by other applicants. If future menthol or other flavor applications succeed using this framework, it could gradually open the authorized market to a wider range of flavors — but each application is reviewed on a product-specific basis, and there is no guarantee the JUUL2 reasoning will transfer automatically.

5. Nicotine Pouch Pipeline Will Expand

With 43 authorized nicotine-pouch products (20 ZYN + 6 on! PLUS + 4 additional on! + 11 ZYN ULTRA + 2 additional ZYN) and the PMTA pilot program accelerating reviews, the oral nicotine category is moving faster than e-cigarettes through the regulatory pipeline. New York's 75% wholesale tax on pouches (effective September 1) shows that states will tax this category aggressively even as the federal market expands.

The Bigger Picture: 48 Products and Counting

The JUUL2 authorization is not an isolated event. It is part of a broader acceleration in FDA tobacco product reviews during 2026:

• March 2026: FDA authorized the Glas G2 device and Blonde Tobacco pod (2 products)
• May 2026: FDA authorized 4 additional Glas pods, including the first-ever non-tobacco/menthol flavors (mango and blueberry) — a watershed moment for flavor policy
• August 2026: FDA authorized 3 JUUL2 products, plus 15 nicotine-pouch products across two manufacturers

That brings the 2026 total to 9 new e-cigarette authorizations and 15+ nicotine-pouch authorizations. The regulated product market is expanding — but it remains a fraction of the total products available in US stores. The FDA continues to prioritize enforcement against unauthorized products, particularly those most appealing to youth.

The question for the rest of 2026 and into 2027 is whether a growing pool of authorized products will materially shift the market toward products that have completed federal premarket review, or whether the gray market — unauthorized disposables, counterfeit pods, and cross-border online sales — will continue to dominate volume. Early evidence from states like Wisconsin, where new regulations triggered an 80% sales decline for some independent shops, suggests that the transition will be disruptive for the retail sector regardless of the outcome.

Sources & Further Reading